~(32)P-玻璃微球治疗原发性肝癌的临床研究

目的:探讨~(32)p-玻璃微球(~(32)P-GMS)综合化疗栓塞治疗中晚期原发性肝癌的临床效果。材料与方法:1995年6月～1999年6月,32例中晚期原发性肝癌分为2组,第一组16例,系~(32)P-GMS综合化疗栓塞组,首先注入~(32)P-GMS超液化碘油悬浮液,然后注入3联化疗药,最后用明胶海绵颗粒栓塞第二组16例,系单纯化疗栓塞组。结果:~(32)P-GMS综合化疗栓塞组16例中,9例肿瘤缩小大于50％,6例AFP降至正常,12例生存超过24个月,肿瘤缩小率及AFP下降率两组比较均有显著差异性。~(32)P-GMS综合组12个月、18个月和24个月生存率分别为87.5％、81.0％、75.5％,而单纯化疗栓塞组分别为56％、31％、18.7％,统计学处理亦有显著性差异。结论:~(32)p-GMS是治疗中晚期原发性肝癌可行的内放射性核素之一,采用~(32)P-GMS综合化疗栓塞是提高治疗原发性肝癌患者生存率的有效方法。

Hepatic Radioembolization with ~(32)P Glass Microspheres for the Treatment of Hepatocellular Carcinoma

Purpose: To evaluate the clinical effects of hepatic radioembilization with 32P glass microspheres for the treatment of hepatocellular carcinoma. Materials and Methods: During the period of Jun 1996-Jun 1999, hepatic radioembolization was performed in 32 patients with hepatocelular carcinoma, who were divided into two groups. After the suspension of 32P with ultrafluid lipidol chmotherapeutic agents were administered via hepatic artery, then hepatic arteries were embolized with Gelfoam particles in group one (16 cases). Chemotherapeutic agents for group two (16 cases) were only administered via hepatic artery. Results: Significant reduction of the tumor size more than 50% was observed in 9 case in group one. Serum AFP level was reduced into normal in 6 cases. The survival rate of 12 cases in group one were more than 24 months. Reduction of the tumor size and the ratios of decrease in sernm AFP level for group one were significantly greater than those in group two (P<0.01). 12 months, 18 months, and 24 months survival rates were 87. 5% , 81. 0% , 75.5% in group one, respectively, 56%, 31%, 18.7% in group two. Conclusion; 32P glass microspheres is one of the most effective radio-isotopes in treatment of HCC. It was an efficent method of increasing the survival rate.